This summary was created by AI, based on 1 opinions in the last 12 months.
Reckitt Benckiser (RBGLY-OTC) has faced significant scrutiny from experts, particularly due to a controversial incident involving its high-risk infant formula, which tragically resulted in the death of a baby. As a result, the company has been dealt a $60 million judgment, alongside billions more in lawsuits anticipated. These developments have evidently influenced investor sentiment. One expert noted that despite having previously endorsed Reckitt as a top pick, the recent events lead to doubts about its future performance. When contemplating an investment in the company today, this expert concluded that they would not choose to buy, reflecting a broader concern about Reckitt's stock outlook.
Their pharmaceutical division is about 20% of their total revenues. 80% of the business is doing well but 20% is going to suffer a little bit when their big drug comes off patent. Watch the stock and see if there is an entry level a lower price from here. Very good company. Executes extremely well on the products that they have. Margins are high. Dividend growth over time is there.
Is it a good entry point after their big drug goes off-patent? When companies come off patent, it really comes down to the quality of the management team. This company’s management has done a terrific job at growing earnings, cash flow, dividends and sales. Doesn’t think it would be that great a concern that one of their drugs is coming off patent because they can just turned around given that they’ve got more of the consumer product business as a backdrop.
Reckitt Benckiser is a American stock, trading under the symbol RBGLY-OTC on the US OTC (RBGLY). It is usually referred to as OTC:RBGLY or RBGLY-OTC
In the last year, 1 stock analyst published opinions about RBGLY-OTC. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Reckitt Benckiser.
Reckitt Benckiser was recommended as a Top Pick by on . Read the latest stock experts ratings for Reckitt Benckiser.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Reckitt Benckiser In the last year. It is a trending stock that is worth watching.
On 2025-04-17, Reckitt Benckiser (RBGLY-OTC) stock closed at a price of $13.
He recently sold. Sadly, baby died from its high-risk infant formula. $60M judgement. Billions more in lawsuits just waiting in the wings. Asked himself if he'd buy today if not already owned, the answer was no, so he sold.